Alitair Pharmaceuticals has entered a definitive agreement to license Erdosteine, a mucolytic compound with antibacterial, anti-inflammatory, and antioxidant properties, from Edmond Pharma for development as an orphan drug in the U.S. and Canada. Financial terms were not disclosed.   Alitair president and chief executive officer William Howard said, “We are delighted to have licensed Erdosteine from Edmond Pharma. Erdosteine is currently approved in 30 countries for the treatment of chronic bron...